Entry Point Capital, LLC Macrogenics Inc Transaction History
Entry Point Capital, LLC
- $171 Million
- Q3 2024
A detailed history of Entry Point Capital, LLC transactions in Macrogenics Inc stock. As of the latest transaction made, Entry Point Capital, LLC holds 28,173 shares of MGNX stock, worth $81,701. This represents 0.05% of its overall portfolio holdings.
Number of Shares
28,173Holding current value
$81,701% of portfolio
0.05%Shares
2 transactions
Others Institutions Holding MGNX
# of Institutions
133Shares Held
55.5MCall Options Held
215KPut Options Held
238K-
Bellevue Group Ag Kuesnacht, V89.93MShares$28.8 Million0.55% of portfolio
-
Armistice Capital, LLC New York, NY6.26MShares$18.1 Million0.34% of portfolio
-
Black Rock Inc. New York, NY5.4MShares$15.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.36MShares$12.6 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.54MShares$10.3 Million0.01% of portfolio
About MACROGENICS INC
- Ticker MGNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,458,800
- Market Cap $178M
- Description
- MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...